JO
KROS icon

John Overdeck’s Keros Therapeutics KROS Stock Holding History

John Overdeck’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.64M Sell
246,649
-117,186
-32% -$1.31M ﹤0.01% 2754
2026
Q1 		$4.02M Buy
363,835
+45,396
+14% +$701K ﹤0.01% 2169
2025
Q4 		$6.48M Buy
318,439
+235,916
+286% +$4.14M 0.01% 1471
2025
Q3 		$1.31M Buy
82,523
+69,001
+510% +$1.02M ﹤0.01% 2412
2025
Q2 		$181K Sell
13,522
-48,850
-78% -$660K ﹤0.01% 2934
2025
Q1 		$636K Buy
62,372
+28,708
+85% +$333K ﹤0.01% 2413
2024
Q4 		$533K Buy
33,664
+23,342
+226% +$1.21M ﹤0.01% 2509
2024
Q3 		$599K Sell
10,322
-25,957
-72% -$1.28M ﹤0.01% 2380
2024
Q2 		$1.66M Buy
36,279
+11,457
+46% +$616K ﹤0.01% 1670
2024
Q1 		$1.64M Sell
24,822
-6,750
-21% -$400K ﹤0.01% 1621
2023
Q4 		$1.26M Buy
+31,572
New +$990K ﹤0.01% 1941
2022
Q3 		– Sell
-55,561
Closed -$1.53M – 2650
2022
Q2 		$1.53M Buy
+55,561
New +$2.44M 0.01% 1332
2021
Q4 		– Sell
-26,404
Closed -$1.04M – 4585
2021
Q3 		$1.04M Sell
26,404
-2,544
-9% -$90.5K ﹤0.01% 2579
2021
Q2 		$1.23M Buy
28,948
+20,470
+241% +$1.11M ﹤0.01% 2300
2021
Q1 		$522K Sell
8,478
-15,999
-65% -$1.01M ﹤0.01% 2888
2020
Q4 		$1.73M Buy
+24,477
New +$1.54M 0.01% 1589

Other funds holding KROS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

John Overdeck's KROS Position: Q2 2026 in Review

John Overdeck reduced its Keros Therapeutics (KROS) stake by 32% in Q2 2026, selling an estimated $1.31M and leaving 246,649 shares worth $2.64M. The position accounts for ﹤0.01% of the portfolio, ranked #2754.

John Overdeck first reported a position in KROS in Q4 2020 and has held it in 16 quarters since. The position peaked at $6.48M in Q4 2025. 131 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

  • John Overdeck held 246,649 shares of Keros Therapeutics worth $2.64M as of Q2 2026.
  • John Overdeck sold 117,186 Keros Therapeutics shares in Q2 2026, an estimated $1.31M.
  • Keros Therapeutics made up ﹤0.01% of John Overdeck's portfolio in Q2 2026, its #2754 holding.
  • John Overdeck first reported a position in Keros Therapeutics in Q4 2020 and has held it in 16 quarters since.
  • John Overdeck's Keros Therapeutics position peaked at $6.48M in Q4 2025.
  • 131 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.